A 60-year-old female presented with metastatic clear cell carcinoma of kidney in December 2007. Her right kidney was excised and subjected to histopathology examination. It revealed pathological stage TNM- pT3 N1 M1. Her complaints were pain in abdomen and frequent urination. She presented with weight loss and anemia.
She was given the option of DENVAX, dendritic cell-based immunotherapy. She received five doses at monthly interval. In three doses, her complaints began to resolve and was back to her normal self in five doses. Intermittently, she continued to receive DENVAX therapy.

She was again evaluated in March 2011 for routine check up and was further advised to received additional DC therapies. Her reports indicate no active disease. Overall her health is good and she does all her normal activities without any assistance.

She is completing 4 years of her quality life without receiving chemotherapy, monoclonal antibodies or interferons and is maintained on dendritic cell therapy.